Related Experiment Videos
[Recent trend and development of novel antimicrobial agents for MRSA infections]
1Department of Microbiology, Kyoto Pharmaceutical University.
Abstract:
Gram-positive organisms such as Staphylococcus aureus (including MRSA), coagulase-negative staphylococci, Enterococcus spp., and Streptococcus spp. have in recent years emerged as significant pathogens in hospitals and are now being isolated more frequently than gram-negative bacilli. These organisms are often multidrug resistant. Therefore, alternative agents with potent activity against gram-positive organisms are of considerable interest. In addition to the glycopeptide antibiotic vancomycin and the aminoglycoside antibiotic arbekacin, which can be used in MRSA infections, teicoplanin, RP 59500 and daptomycin are now under basic research in Japan. These antimicrobial agents are very active against gram-positive organisms, including MRSA and appear to be potent agents against infections due to gram-positive cocci, particularly MRSA.
Insights
Emerging multidrug-resistant Gram-positive pathogens like MRSA are a growing hospital concern. New antimicrobial agents, including teicoplanin, RP 59500, and daptomycin, show potent activity against these resistant infections.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Context:
- Gram-positive organisms, including Methicillin-resistant Staphylococcus aureus (MRSA), are increasingly prevalent hospital-acquired pathogens.
- These multidrug-resistant (MDR) bacteria pose significant treatment challenges, often surpassing Gram-negative bacilli in isolation frequency.
- The rise of MDR Gram-positive infections necessitates the development of novel therapeutic strategies.
Purpose:
- To review emerging antimicrobial agents with potent activity against Gram-positive organisms, particularly MRSA.
- To highlight novel antibiotics under investigation for treating infections caused by resistant Gram-positive cocci.
- To assess the potential of alternative agents beyond vancomycin and arbekacin for MRSA infections.
Summary:
- New antimicrobial agents like teicoplanin, RP 59500, and daptomycin are under investigation in Japan.
- These agents demonstrate significant in vitro activity against a range of Gram-positive bacteria, including MRSA.
- They represent promising alternatives for managing infections caused by multidrug-resistant Gram-positive cocci.
Impact:
- These novel agents could provide crucial treatment options for challenging MRSA and other Gram-positive infections.
- Successful development may help combat the growing threat of antimicrobial resistance in hospital settings.
- Further research and clinical trials are essential to establish the efficacy and safety of these promising antibiotics.